The Association of Non Viral Liver Diseases from NAFLD to NASH  to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity  & Metabolic Syndrome Etiopathogenetic Correlation along with Utilization for Diagnostic & Therapeutic Purposes-A Systematic Review by Kaur, Kulvinder Kochar et al.
10 Distributed under creative commons license 4.0
Journal of Endocrinology Research | Volume 03 | Issue 02 | July 2021
https://ojs.bilpublishing.com/index.php/jer/index
Journal of Endocrinology Research
*Corresponding Author:
Kulvinder Kochar Kaur,




The Association of Non Viral Liver Diseases from NAFLD to NASH 
to HCC with the Pandemic of Obesity, Type 2 Diabetes, or Diabesity 
& Metabolic Syndrome Etiopathogenetic Correlation along with Uti-
lization for Diagnostic & Therapeutic Purposes-A Systematic Review
Kulvinder Kochar Kaur1*   Gautam Allahbadia2   Mandeep Singh3
1. Kaur Centre For Human Reproduction, 721, G.T.B. Nagar, Jalandhar, Punjab, 144001, India
2. Ex-Rotunda-A Centre for Human Reproduction, 672, Kalpak Garden, Bandra(W)-Mumbai, 400040, India
3. Swami Satyanand Hospital, Jalandhar, Punjab, India
ARTICLE INFO ABSTRACT
Article history
Received: 4 August 2021
Accepted: 15 August 2021 
Published Online: 25 August 2021
Earlier we have been reviewing the etiopathogenesis (EP) of obesity, type2 
Diabetes mellitus (T2DM), Metabolic Syndrome (MetS), Non Alcoholic 
Fatty Acid Liver Disease (NAFLD) non alcoholic steatohepapititis 
(NASH), along with its propagation to Hepatocellular carcinoma (HCC) 
in addition to their therapies exhaustively. T2DM continues to be a major 
health issue with reaching epidemic to pandemic proportions. Liver disease 
includes a spectrum of liver injury varying from isolated steatosis known 
as Non Alcoholic Fatty Acid Liver Disease (NAFLD) to HCC. Clinically 
it has been observed that the coexistence of NAFLD as well as T2DM is 
prevalent. T2DM aids in the biological events that results in escalation 
of robustness of NAFLD that constitutes the primary etiology of chronic 
liver diseases. In the past 2 decades the incidence of nonviral NAFLD/
NASH, obtained HCC has been escalating at a fast pace. In view of no 
appropriate agents for therapy of NAFLD/NASH, a thiazolidenedione 
group of drug pioglitazone used for T2DM therapy is utilized occasionally. 
Thus here we conducted a systematic review utilizing search engine 
pubmed, google scholar; web of science; embase; Cochrane review 
libraryutilizingtheMeSHterms like T2DM; MetS; NAFLD; NASH; HCC; 
WAT; BAT; VisceralAT; Obesity; BMI; Adipocytokines; adiponectin; 
leptin; resistin; visfatin; irisin; Hepatokines; angiopoietin like protein 
2; hepatosscin; retinol binding protein 4; treatment like pioglitazone; 
liraglutide; elafibranor CVC (cerviciroc); obeticholic acid; aramchol; 
selonosertib; simtuzumab; Oxidative stress(OS); insulin resistance (IR) 
from 1980’s to 2021 till date. We found a total of 1050 articles out of which 
we selected 236 articles for this review. No meta-analysis was done. Hence 
diagnosis avoidance in addition to treatment of the generation as well as 
propagation of NAFLD/NASH are significant areas needing tackling. Thus 
here we have summarized the EP of NAFLD/NASH, as well as NAFLD/
NASH, obtained HCC along with the present advantageous therapies under 
trial, for NAFLD/NASH. Moreover how adipocyte obtained adipokines 
along with liver obtained hepatokines might work as both diagnostic in 
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1. Introduction
Earlier we have been reviewing the etiopathogenesis 
(EP) of obesity, type2 Diabetes mellitus (T2DM), Meta-
bolic Syndrome (MetS), Non Alcoholic Fatty Acid Liver 
Disease (NAFLD) non alcoholic steatohepapititis (NASH), 
along with its propagation to Hepatocellular carcinoma 
(HCC) in addition to their therapies exhaustively [1-24] 
[besides many more]. T2DM, altogether with obesity, 
NAFLD represents the commonest liver disease, associat-
ed -in about 30% of the general population [25]. The prop-
erties of NAFLD are hepatic triglycerides (TG), collection 
in addition to insulin resistance (IR) [26]. This is basically 
the hepatic presentation of Metabolic Syndrome (MetS) 
along with spans a problem encompassing benign with 
hepatic steatosis to NASH [27]. Widely the 2 are clubbed as 
Non Alcoholic Fatty Acid Liver (NAFL) as well as NASH 
[28]. NAFL represents isolated steatosis, whereas NASH 
possesses properties of steatosis, lobular inflammation 
(alias infiltration by inflammatory cells), hepatocellular 
ballooning in the existence or absence of fibrosis [29]. 
NASH is the one having maximum aggressiveness of the 
NAFLD, possesses capacity of propagation to continuous 
fibrosis, with a direct correlation with the risk of Hepato-
cellular carcinoma (HCC) generation that might be a ma-
jor reason for morbidity as well as mortality stimulated by 
liver failure (Figure 1) [25,30]. Prevalence of NASH is about 
30% in case of patients with NAFLD [31]. Roughly 20% of 
patients with NASH having fibrosis propagate to cirrhosis 
[32]. Liver cirrhosis exists in just 50% of NAFLD-associat-
ed HCC [33]. Incidence of NAFLD-associated HCC with-
out cirrhosis is about 8% of total HCC patients [34], while 
total incidence rate of HCC in NAFLD as well as NASH 
varies from 2-13% [35].
In the clinical scenario NAFLD is present along with 
T2DM, obesity, influencing synergism action resulting in 
greater robust liver failures [36]. Prevalence of NAFLD is 
thought to be about 75% in cases with T2DM along with 
90% in obese cases, that point to a significant association 
of NAFLD with T2DM along with obesity [37]. NAFLD 
participates significantly in escalated incidence of T2DM 
in addition to its complications [28]. Further T2DM exac-
erbates NAFLD as well to a more robust type of NASH, 
fibrosis as well as HCC (Figure 1) [37,38]. 
HCC, represents a highly aggressive cancers [39]. Earlier 
hepatitis C virus was believed to the commonest etiology 
of HCC [40], although recently it has been illustrated that 
till 50% of new onset HCC cases did not have a viral 
etiology [41]. The causation of NAFLD/NASH stimulated 
HCC is highly complicated, which is correlated with a lot 
of modes like cellular plasticity, inflammation, apoptosis, 
cell cycle as well as cell demise [42]. Hence therapy of 
HCC is tough. Moreover it is essential that concentration 
is done for avoidance of NAFLD/NASH propagation by 
treating them earlier as well as avoidance of its propaga-
tion towards irreversible chronic liver Diseases like cir-
 
Figure 1. The progression of NAFLD/NASH to HCC
Legend for Figure 1
Courtesy ref no-30-Type 2 diabetes and obesity aggravate the progression of NAFLD/NASH to HCC. Clinically, type 2 diabetes 
coexists with NAFLD, and it aggravates NAFLD to more severe forms of NASH, hepatocirrhosis, and HCC, leading to a 
metabolically worse phenotype.
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rhosis as well as HCC. No FDA approved drugs exist till 
date.
Besides have reviewed a lot of therapies for NAFLD, 
trials under way for NAFLD/NASH therapy, we had re-
viewed the role of adipocytokines in obesity as well as 
T2DM associated heart failure (HF). Here we have tried 
to update on EP of NAFLD/NASH, as well as NAFLD/
NASH associated HCC, besides the present beneficial 
therapies for NAFLD/NASH under trials. Moreover the 
initiation of as well as propagation can get influenced 
by adipokines/organokines liberated from Metabolic or-
gans when Metabolic impairment exists like T2DM as 
well as obesity [43]. Thus here we have concentrated on 
organokines liberated by AT as well as liver. That are key 
organs for controlling of lipid metabolism. Newer under-
standing with regards to adipoklines/hepatokines which 
might serve as potential diagnostic as well as therapeutic 
targets in NAFLD/NASH as well as NAFLD/NASH ob-
tained HCC. These are believed to be biological markers 
which can anticipate robustness of NAFLD from NAFLD 
to HCC.
Thus here we carried out a systematic review on the 
association of various metabolic disturbances in the initi-
ation of various liver disorders ranging from NAFLD to 
NASH and further towards HCC.
2. Methods
Thus here we conducted a systematic review utilizing 
search engine pubmed, google scholar; web of science; 
embase; Cochrane review library utilizing the MeSH 
terms like T2DM; MetS; NAFLD; NASH; HCC; WAT; 
BAT; VisceralAT; Obesity; BMI; Adipocytokines; adi-
ponectin; leptin; resistin; visfatin; omentin; irisin; Hepa-
tokines; angiopoietin like protein 2; hepatosscin; retinol 
binding protein 4; treatment like pioglitazone; liraglutide; 
elafibranor CVC (cerviciroc); obeticholic acid; aramchol; 
selonosertib; simtuzumab; Oxidative stress(OS); insulin 
resistance (IR) from 1980’s to 2021 till date.
3. Results 
We found a total of 1050 articles out of which we se-
lected 236 articles for this review. No meta-analysis was 
done.
4. Discussion
4.1 Etiopathogenesis (EP) of Non Alcoholic Fatty 
Acid Liver Disease (NAFLD) as well as Non 
Alcoholic Steatohepapititis (NASH)
Disturbed Balance -among fatty acids(FA) Metabolism
NAFLD represents the commonest cause of chronic 
liver disease. NAFLD occurs, secondary to escalated 
triglycerides (TG), collection in the liver [26]. Hence the 
balance among FA input as well as -output is key [44]. Im-
plying that generation of NAFLD takes place if levels of 
exogenous FA uptake (by dietary ingestion along with ad-
ipose tissue (AT) lipolysis) as well as endogenous FA gen-
eration (DNL in liver is greater than the liberation of FA 
(FA oxidation, lipolysis, as well as FA liberation in very 
low density lipoprotein (VLDL) TG) from liver (Figure 2).
The liberation of FA from AT as well as effectiveness 
of FA uptake by liver are escalated by about 59% in cases 
of NAFLD [45], Liver FA is based on the number as well 
as action of specific FA transporter as well as FA carrier 
proteins like FA translocase (FAT, CD36), FA transport 
polypeptide [FAT]) as well as, fatty acids binding protein 
(FABP) [46]. Like hepatic expression of FAT/CD36 is sig-
nificantly escalated in cases with NAFLD, as well as he-
patic expression of FABP4 as well as FABP5 is intricately 
correlated with intrahepatic TG collection.
In about 26% of patients, the method of aiding liver FA 
pool is hepatic Denovo lipogenesis (DNL) [47]. DNL rep-
resents metabolic event which is implicated in generation 
of new FA from escalated glucose [48]. It significantly aids 
in hepatic lipid collection in etiopathogenesis of NAFLD 
[48]. The activation of 2 Transcription factors (of sterol reg-
ulatory element binding protein 1c (SREBP1c), as well as 
carbohydrate responsive element binding protein [ChRE-
BP]), enhanced by insulin as well as glucose reaction to 
dietary carbohydrate [49]. They possess synergistic signif-
icant part in coordinated control of hepatic DNL. In rest 
15% of patients of NAFLD, FA pool is obtained from diet 
TG. That is correlated with chylomicron [45].
The maximum lucrative theory in etiopathogenesis of 
NAFLDis “2hit’’ posit [50]. 1st hit is IR, secondary to esca-
lated FA flux, 2ND is inflammation, correlated with gut ob-
tained endotoxins, Oxidative stress (OS) as well as mito-
chondrial impair. It is intricately associated with NAFLD-
NASH.
Endotoxin behavior
NAFLD as well as other insulin resistance (IR) dis-
ease are correlated with activation of innate immune 
system=>chronic inflammation [51]. Recently gut obtained 
endotoxin, like lipopolysaccharides (LPS) have been 
posited to possess a key part in liver inflammation sec-
ondary as well as propagation to chronic Liver Disease [52]. 
Normally, Endotoxin can get absorbed from the lumen of 
the intestine into theportal venous system in addition to 
absorbed endotoxin would get cleared fast by the reticulo 
endothelial system, specifically kupffer cells [53]. Never-
DOI: https://doi.org/10.30564/jer.v3i2.3520
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theless, obesity, type2 Diabetes mellitus (DM) along with 
other nutritional parameters can change intestinal per-
meability as far as bacterial excessive growth leading to 
amucosal barrier that becomes leaky resulting in bacterial 
transportation, that points to the liberation of endotoxin 
into the systemic circulation [54]. These invasive pathogen-
ic deleterious by products have an impact on the liver li-
pid collection along with acceleration of proinflammatory 
in addition to fibrosis events [53].
The part of LPS from gut microbiota (GM) in the gen-
eration of NAFLD as well as NASH has been highlighted 
[54]. Circulating LPS amounts small intestinal permeability, 
along with bacterial excessive growth are escalated in 
cases of NAFLD, with these factors being correlated with 
the robustness of hepatic steatosis [54,56]. Livers getting 
blood directly from the portal vein remain the major tar-
gets of LPS, alias endotoxin, with LPS toll like receptor 4 
(TLR4) being one of the key pathways for the generation 
of NAFLD. In case of mouse models, LPS infusion caus-
es stimulation of hepatic steatosis in addition to hepatic 
insulin resistance, along with hepatic weight escalation 
[57]. LPS results in acceleration of liver damage in mice 
receiving a diet lacking methionine-choline [58]. The LPS 
binding protein LBP-CD14 complex results in stimulation 
of TLR4, that is necessary cascade needed for inflamma-
tory propagation [59]. Once LBP deletion occurs it ame-
liorates inflammation modulated liver damage [60]. TLR4 
possesses the characteristics of stimulation of nuclear fac-
tor κB (NFκB) in addition to liberation of proinflammato-
ry cytokines like interleukin-1β (IL-1β), Tumor necrosis 
factor alpha (TNFα) as well as IL-6 [61]. Further it has the 
ability of recalling damage associated molecular patterns 
(DAMP), which get liberated from damaged cells, as well 
as modulates FA-stimulated inflammation [51,62]. In the 
form of -Pharmacological treatmentsin NAFLD as well 
as NASH which target the microbiome, IMM-24 (an anti- 
LPS antibody), solithromycin (next generation macrolide 
antibiotic) along with TLR4 antagonist [63].
Oxidative stress
Chronic Oxidative stress (OS) is crucial modes re-
sulting in liver damage in NAFLD. Oxidative stress is a 
 
Figure 2. NAFLD development: An imbalance in FA metabolism
Legend for Figure 2
Courtesy ref no-30-NAFLD development is caused by an imbalance in the intrahepatocellular fatty acid (FA) metabolism. Hepatic 
TG accumulation is promoted when the FA input is greater than the FA output in the liver. The greater part of FA taken up by liver 
is mainly derived from the lipolysis of subcutaneous adipose tissue TG. Another major source of FA in the liver is derived from de 
novo lipogenesis that converts excess glucose into FAs. On the other hand, the consumption of FA is possible through the signaling 
pathway involved in lipolysis, β-oxidation, and TG secretion (→: signaling pathways related with TG accumulation by FA, →: 
signaling pathways related with the consumption of FA).
DOI: https://doi.org/10.30564/jer.v3i2.3520
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process occurring generally in NAFLD as well as NASH 
secondary to escalated generation of Reactive oxygen 
species (ROS) [64]. ROS in addition to lipid per oxida-
tion can reason out maximum histological parameters of 
NAFLD as well as NASH [65]. In case of hepatic steatosis 
patients, mitochondrial ROS Oxidizes hepatic fat depos-
its along with ROS stimulated Fas ligand expression can 
generate apoptosis [65]. Both peroxidation of along with 
intra cellular membrane can directly result in apoptosis 
stimulation as well as necrosis [65]. The robustness of lipid 
peroxidation is associated with the robustness of steatosis 
in addition to can reason out the correlation among the ro-
bustness of steatosis in addition to the chances of necrosis 
inflammation along with fibrosis in NASH [66]. ROS that 
is a critical factor in the etiopathogenesis of NASH, can 
result in a self created cycle of lipid peroxidation as well 
as further cause ROS generation [67]. Alteration of -mito-
chondrial DNA can result secondary to products generated 
by lipid peroxidation as well as result in stimulation of 
the transcription factor nuclear factor κB (NFκB), which 
causes upregulation of TNFα [68]. Hence it further aids in 
dysfunctional mitochondrial respiration in addition to es-
calation of ROS generation [68].
Escalation of mitochondrial β-oxidation of FFA is a 
significant generator of ROS in NAFLD as well as NASH 
[69]. Enhancement of FFA flux during early NAFLD stage 
cause activation of mitochondrial FA-oxidation (FAO), 
which points to an early liver compensation modes for 
hampering liver fat collection along with sustenance of 
liver lipid homeostasis [26]. In case of NAFLD as well as 
NASH mitochondrial FAO is further escalated or mini-
mum conserves in the form of a compensation reaction. 
The disturbed balance among mitochondrial FAO as well 
as electron transport chain (ETC) would aid in escalation 
of ROS generation by escalated leaking of electrons from 
the ETC [26,69]. ROS stimulated lipid per oxidation results 
in inflammation along with hepatic fibrogenesis via the 
stimulation of hepatic stellate cells (HSC’s) [70].
Trusted circulation markers which might point OS in 
cases with NAFLD have got documented. Urinary 8-iso 
prostaglandin F2α (8-isoPGF2α) is believed to be trusted 
pointer of OS in vivo [71], as well as soluble NOX2-ob-
tained peptide (s-NOX2-dp) are further agreed upon as 
marker that is correlated with ROS production on stim-
ulation of NOX2, that is a member of NADPH-oxidase 
family [72]. Enhancement of urinary amounts of 8-isoP-
GF2α as well as serum soluble NOX2-obtained peptide 
are believed to be [73] trusted pointers of oxidative stress 
in case of chronic inflammation along with metabolic 
disease [73]. Further the utilization of these markers can be 
done for OS regarding anticipation of robustness of liver 
injury in NAFLD [74]. LPS is a significant constituent of 
outer membrane of gram negative bacteria which results 
in stimulation of exacerbation of inflammation as well as 
Oxidative stress [75]. Enhancement of circulating amounts 
of NOX2 as well as LPS in NAFLD point to a potential 
part in gut obtained LPS in systemic NOX2 stimulation [76]. 
Moreover -s- NOX2-dp -amounts -possess a positive cor-
relation of histological grading with steatosis, inflamma-
tion, ballooning, fibrosis as well as NAFLD activity score 
(NAS) [76]. Gut obtained LPS might result in activation of 
TLR4, as well as TLR4 – modulated NOXs activation can 
lead to generation of ROS by macrophage infiltration [77]. 
This can aid to hepatic steatosis in addition to IR [77].
Nevertheless, the variablility of metabolic alterations 
take place in NAFLD are not enough to get reasoned out 
by “2 hit” posit. Maximum metabolic conditions like obe-
sity, T2DM, Metabolic Syndrome (MetS), dyslipidemia 
work as the risk factors for generation of NAFLD by the 
“multiple hits’’ implicating a lot of factors (Figure 3) [78]. 
These “multiple hits’’ are bioactive molecules liberated 
from AT, nutritional factors as well as environmental fac-
tors [78].
4.2 Attractive Treatment in NAFLD as well as 
NASH
With the recently advocated that pioglitazone, along 
with high dosages of Vitamin E, efficaciously result in 
amelioration of escalation of histological alterations in 
cases of NASH [79]. Conversely metformin has no such 
action in NAFLD patients [80], as well as ursodeoxycholic 
acid (UDCA), has no influence on liver histological alter-
ations, inflammation, or fibrosis in patients with NASH 
[82]. Following are certain Pharmacological examples un-
der Clinical trials as well as might work out as promising 
agent for NASH treatment (Figure 4). In addition, the 
metabolic profile along with liver histology correlated ef-
fectiveness of these attractive drugs [19,20,81].
Pioglitazone
Pioglitazone represents an anti diabetic drug thi-
azolidenediones (TZD) class utilized for T2D treatment 
[83]. TZD’S are further referred to as glitazones. Two 
TZD’s are presently approved by FDA for montherapy or 
combination treatment with metformin as well as sulfo-
nylureas for T2D treatment [84]. TZD’s meant for insulin 
sensitization aid in controlling glycemia along with insu-
lin resistance (IR) [84]. The maximum significant benefit of 
TZD’s was that hypoglycemia doesn’t result secondary to 
its utilization with single treatment, with it not being con-
traindicated in patients presenting with renal disease [85].
DOI: https://doi.org/10.30564/jer.v3i2.3520
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Figure 3. NAFLD/NASH: “Multiple-hits”
Legend for Figure 3
Courtesy ref no-30-Multiple-hits pathogenesis of NAFLD and NASH. NAFLD begins with hepatic lipid accumulation and insulin 
resistance, and progresses to NASH with the concert of various factors such as inflammation, endotoxin, organokines (adipokines and 
hepatokines), and oxidative stress. (▪: Factors related with multiple-hits).
 
Figure 4. Pharmacological examples
Legend for Figure 4
Courtesy ref no-30-Current therapeutic targets for pharmacological treatment of NAFLD and NASH. There are no FDA-approved 
medications for patients with NAFLD/NASH so far. Currently, various pharmacological therapeutic candidates are being applied 
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TZD’s work by controlling metabolic pathway by bind-
ing to the nuclear transcription factor Peroxisome Prolifer-
ator adenineActivated Receptor γ (PPAR γ) in addition to 
modulation of the expression of the target genes [86]. The 
genes possess a part in controlling glucose metabolism, 
storage of FA’s along with adipocytes differentiation [87]. 
In agreement with this PPAR γ agonist escalated the ex-
pression of glucose transporter 4 (GLUT4alias SLC2A4) 
A as well as translocation, hamper TNFα as well as result 
in enhancement of insulin sensitivity in case of organs 
which are insulin sensitive [88]. Conversely T2D treatment 
effects increments of weight as an adverse action, since 
PPAR γ Receptor’s are markedly expressed in adipocytes 
[89]. Enhancement of fat mass is restricted to the subcu-
taneous adipose depots instead of the visceral area [88,90]. 
That can be prevented by metformin therapy [91].
Recently it got documented that the PPAR γ agonist 
Pioglitazone possesses significant actions on NAFLD/
NASH patients. In case of patients with NASH, it ame-
lioratedliver fat collection along with fibrosis [92]. In case 
of patients with NASH in addition to T2DM, it results in 
reduction of hepatic steatosis, inflammation as well as se-
rum alanine amino transferase (ALT) as well as aspartate 
amino transferase (AST) with better liver function [93]. In 
rodent models it decreases hepatic gluconeogenesis along 
with results in escalation of insulin sensitivity in the liver 
as well as other peripheral tissues [94].
Obeticholic acid (OCA); or INT-747; Farsenoid X 
receptor [FXR] agonist
Obeticholic acid (OCA) represents a Farsenoid X re-
ceptor [FXR] agonist, that is a nuclear receptor, with sig-
nificant expression in the liver along with small intestine, 
having a significant part in the generation in addition to 
enterohepatic circulation of bile acids, besides controlling 
hepatic glucose as well as lipid metabolism, inflammation 
as well as lipoprotein constituents in addition to bile acid 
generation [95]. In rodent models OCA has anti-inflamma-
tory along with, anti-fibrotic actions on HSC’s as well as 
macrophages [96]. The transcriptional repressor small or 
short heterodimer partner (SHP), crossreacts with liver 
receptorhomolog1 (LRH1), that represents a positive 
controller of CYP7A1 which encodes for the rate limiting 
enzyme in the classic bile acids generation pathway as 
well as represses its ability for transcription [97]. HSC’s 
getting exposed to FXR ligands escalated the expression 
of the transcriptional repressor SHP along with reduction 
of factors correlated with liver fibrosis [96]. Belief is that 
an FXR SHP controlling axis has a significant part in 
controlling liver fibrosis. OCA stimulation of FXR-action 
has 100 times greater potency in contrast to the chenode-
oxycholic acid, that is a natural FXR agonist [98]. Escala-
tion of insulin sensitivity results with the use of OCA in 
addition to, reduction of hepatic inflammation markers as 
well as fibrosis in patients with T2D as well as NAFLD 
[99].Weight reduction results in patients with NASH, with 
this weight reduction having extra advantageous actions 
on SerumALT/ASTamounts along with liver histology [100]. 
In addition to that it results in significant enhances fibrosis 
in patients with NASH [101]. It represents 1 of the agents 
holding maximum promise for NASH therapy, is in phase 
3 trials [102].
Elafibranor (GFT-505; Peroxisome Proliferator 
Activated Receptor (PPAR)-agonist)
PPAR’s represent transcription factors that get activat-
ed by ligand, belonging to the nuclear hormone receptors 
superfamily [103]. Their expression occurs in liver, adipose 
tissue (AT), heart, skeletal muscle, as well as kidney, be-
sides controlling -β -oxidation along with gluconeogen-
esis [102]. Three kinds of nuclear receptor isoforms exist; 
PPARα, PPAR δ, as well as PPARγ. PPARα, facilitates 
β -oxidation, decreases triglycerides (TG), amounts, be-
sides escalated high density lipoprotein (HDL) cholesterol 
amounts [104]. Further it hampers nuclear factor κB (NFκB) 
stimulation of inflammatory genes [104]. PPARα agonists 
like fibric acids derived compounds like fibrates is in 
usage widely for the treatment of hypertriglyceridemia, 
while it doesn’t possess significant actions in NAFLD 
patients [105]. The reason for this is the existence of PPARα 
in a lot of organs besides liver. Akin to PPARα, PPAR δ 
causes escalation of FA oxidation along with decreases 
macrophages in addition to Kupffer cells activation, in 
view of its existence on macrophages [106]. GW50516 
represents a synthetic PPAR δ particular agonist [107]. 
GW50516 can be thought of as attractive proposition in 
Clinical trials, in view of it possessing potent efficiency, 
however it possesses safety issues [108]. 
Elafibranor, alias GFT505 is a double PPARα as well 
as δ agonist [109]. It attenuates inflammation, apoptosis, 
necroptosis in case of NASH mouse model [110]. It led to 
reduction of histological hepatic steatosis, inflammation 
in addition to, robustness of fibrosis in both the NAFLD/
NASH as well as fibrosis mouse model [111]. It has a ten-
dency to result in weight reduction, but not that of liver 
in case of diet stimulated NAFLD/NASH rodent models 
[112]. In cases of obese subjects it enhances hepatic as well 
as peripheral insulin sensitivity [113]. Moreover it hampers 
proinflammatory (interleukin-1β, TNFα as well as F4/80), 
in addition to, profibrotic transforming growth factor 
beta TGF-β, tissue inhibitors of matrix metalloprotein-
ase (TIMP2), collagen type1, alpha2 as well as collagen 
DOI: https://doi.org/10.30564/jer.v3i2.3520
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type1, alpha2 markers in obese subjects [114]. No -weight 
gain was reported [109,115]. Presently it is getting analysed in 
phase 3trials in NASH subjects [102].
Arachidylamido cholanoic acid (Aramchol) 
Stearoyl-Co A Desaturase (SCD1) Inhibitor
Aramchol represents the liver targeted, an innovative 
synthetic lipid molecule,a conjugate of the bile acid, chol-
ic acid as well as arachidic acid (FABACs). It influences 
liver fat metabolism by causing reduction in FA genera-
tion along with escalation of β -oxidation [117]. Furthermore 
it results in stimulation of cholesterol efflux by activation 
of the ATP – binding cassette transporterA1 (ABCA1) [118]. 
Additionally, it decreases inflammation as well as fibro-
sis in methionine as well as choline deficient (MCD) fed 
mice [116]. Moreover it tends to ameliorate steatohepapititis 
as well as fibrosis by causing reduction in SCD1 amounts 
by controlling the transsulfuration pathway resulting in 
escalated glutathione amounts as well as the glutathione 
disulfide (GSSH/GDX redox couple for appropriate bal-
ance of redox environment [116].
In a phase 2 trial, of patients with NAFLD, Aramchol 
decreased the liver fat amounts along with liver histology 
[119]. No significant toxicity was observed as seen in cir-
culating ALT as well as AST amounts, besides alkaline 
phosphatase (AP) amounts [119]. In view of it targeting 
general properties of NASH (like escalated liver fat 
amounts, lipotoxicity as well as OS) in addition to fibrosis 
Aramchol is at present getting generated for NASH treat-
ment along with that of fibrosis. No significant alterations 
in body weight was observed in NASH patients. Phase 3 
clinical trials are ongoing in patients with NASH as well 
as fibroses got started in 2019.
Liraglutide (GLP-1Agonist)
Glucagon like peptide 1 receptor (GLP-1) agonists 
have got well proven -in the form of attractive anti Dia-
betic agent in animals as well as - patients with T2DM [120]. 
GLP-1 represents an incretin hormone liberated from the 
L-cells in the distal ileum along with colon [121]. It causes 
stimulation of pancreas resulting in insulin generation, in 
addition to decreases glucagon generation [122]. Endoge-
nous GLP-1 gets broken down by Dipeptidyl Peptidase-4 
(DPP-4) enzyme within few minutes whereas Liraglutide 
possesses long half life 13h [123].
Exenatide that is a synthetic Extendin-4 was the 1st 
GLP-1R agonist that got FDA approval in 2005 for T2DM 
treatment in form of monotherapy or as add on therapy 
with metformin as well as or sulfonyl urea, in case control 
was not sufficient [124].
Liraglutide, the second GLP-1R agonist that got a li-
cense in 2010 by FDA for T2DM treatment. Further in 
2020 it got FDA approval for therapy of obesity patients, 
dependent on its weight reduction advantages [125]. It pos-
sesses cardiovascular safety while treatment for weight re-
duction [126]. Anorexia secondary to Liraglutide is associat-
ed with glutamatergic POMC neurons, resulting in weight 
reduction [127]. In cases of NAFLD as well as NASH it 
causes reduction in liver fat amounts, besides with liver 
histology getting rectified along with normalization of en-
zymes (ALT as well as AST amounts) without deterioratri-
on of fibrosis [128]. In view of rodent studies demonstrating 
Liraglutide conferred protection to pancreatic β cells from 
apoptosis via AKT modulated survival signaling [129]. 
It enhanced insulin sensitivity by activation of adenine 
monophosphate activated -protein kinase (AMPK) as well 
as decreases hepatic steatosis by modulation of lipid trans-
portation, β-oxidation, DNL, as well as autophagy [130].
Selonsertib (ASK1 Inhibitor)
Balooning of hepatocytes, points towards the stim-
ulation of the apoptosis pathway, which represents a 
hallmark of NASH along with fibrosis propagation [131]. 
Selonsertib represents -1ST in class Inhibitor of the apop-
tosis signal regulating kinase 1 (ASK1) [132]. Selonsertib 
hampers phosphorylation as well as activation of ASK1 
by binding to the catalytic kinase domain of ASK1. It has 
been posited recently possessing therapeutic potential for 
fibrotic Diseases. In case of murine models, ASK1, that 
is a serine/threonine kinase, results in phosphorylation of 
p38 mitogen activated protein kinase (MAPK) as well as, 
resulting in activation ofc-Jun –N terminal kinase (JNK) 
resulting in activation of stress response pathways which 
exacerbate hepatic inflammation, apoptosis in addition to 
fibrosis [133]. In murine models of NASH, it significantly 
enhances besides hepatic steatosis in addition to fibrosis 
correlated with NASH, enhancement of cholesterol, the 
bile acid and lipid metabolism [133]. In phase 2 Clinical 
trials of NASH patients as well as stage 2-3 fibrosis, it has 
got demonstrated to avoid inflammation, fibrosis, escalat-
ed apoptosis as well as -propagation to cirrhosis [134]. Con-
versely, phase 3 Clinical trials of NASH patients along 
with advanced fibrosis were observed to escalate liver 
histology, but had no influence on fibrosis regression [135].
Simutuzumab (SIM;G6624)
Simutuzumab (SIM) represents a monoclonal Ab,that 
targets lysyl oxidase –like 2 (LOXL2) enzymatic activity 
which catalyzes the crosslinlinking of collagen in addition 
to elastin, resulting in remodeling of the extra cellular ma-
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trix (ECM) [136]. SIM binds TO LOXL2 as well as hampers 
its enzymatic action [137]. Hence it hampers the generation 
of growth factors that includes [connective tissue growth 
factor (CTGF]/CCN2) as well as TGFβ1 in addition to 
results in reduction of fibrosis [138]. In a mouse model 
possessing advanced fibrosis stimulated by NASH, SIM 
possesses an extra action in combination with the ASK1 
Inhibitor [134]. Nevertheless, in phase 2b clinical trials of 
patients presenting with advanced fibrosis secondary to 
NASH it did not display any action on enhancement of 
fibrosis or cirrhosis that had been verified by hepatic col-
lagen amounts [139].
C-C chemokine receptor CCR Dual -types -2 as 
well as 5 (CCR2/CCR5) antagonist -(cenicriviroc)
Liver inflammation is intricately correlated with 
chemokines responsible for controlling migration of 
hepatocytes as well as immune cells [140]. The C-C 
chemokine receptor 2 as well as 5 (CCR2, as well as 
-CCR5) with their associated ligands CCL2 as well as 
CCL3-5) have a correlation with the pathogenesis of Liver 
inflammation as well as fibrosis in the generation of [140,141]. 
CCR2 in addition to its ligand CCL2 escalated hepatic ste-
atosis, macrophages collection, inflammation along with 
fibrosis [140]. Hepatic Stellate cells (HSCs) on activation, 
aid in fibrosis, liberate CCL5. CCL5 influences profibrotic 
action in hepatocytes through its receptor CCR5 as well as 
results in stimulation of lipid collection as well as proin-
flammatory factors [141].
CVC or cenicriviroc represents an innovative CCR2, 
as well as CCR5 antagonist which is at present in Clin-
ical generation for the therapy of liver fibrosis patients 
presenting with NASH [142]. CVC results in reduction of 
markers of inflammation like IL-1β, IL-6 as well as influ-
ences antifibrotic actions [142]. Fast track movement was 
given by FDA in 2015, being a highly lucrative therapy 
for NASH as well as liver fibrosis. In a phase 2b study of 
NASH patients presenting with stage 2-3 fibrosis, CVC 
-demonstrated enhancement in liver fibrosis. In addition to 
no deterioration in -NASH [143]. At present a phase 3 clin-
icaltrial is ongoing for the therapy of NASH cases with 
liver fibrosis [144].
4.3 Diagnostic Approaches as well as Therapeutic 
Targets  in  NAFLD as  we l l  as  -  NASH –
Adipocytokines 
It is thought that NAFLD as well as NASH are sec-
ondary to lots of etiopathogenetic factors [78]. Of these we 
concentrate on adipokines liberated from adipose tissue 
(AT) which yield fatty acids (FA) as the main site aid-
ing for NAFLD generation [45]. Various Adipokines are 
implicated in the pathogenesis as well as propagation of 
NAFLD [145]. Leptin, resistin, in addition to visfatin have 
a part in NAFLD generation as well as propagation of 
NASH [145,147]. Conversely adiponectin, irisin as well as 
ghrelin have advantageous actions on NAFLD as well as 
NASH [148,149]. Pharmacological drugs which impact liver 
histology along with pathophysiology might affect these 
adipocytokines amount. This points that adipocytokines 
could prove to be significant therapeutic targets as well as 
biomarkers in NAFLD robustness anticipation (Figure 5). 
These adipocytokines might further have a significant role 
in generation of HCC.
Adiponectin
Adiponectin is a significant Adipocytokines possessing 
the ability to hamper NAFLD generation. A reduction of 
circulating amounts of Adiponectin was found in cases 
of NAFLD as well as NASH [150]. They had an inverse 
association with the robustness of hepatic steatosis as well 
as inflammation. Pioglitazone, the antidiabetc which had 
a beneficial action on liver histology escalated adiponec-
tin amounts, in patients withNASH [93]. Nevertheless, 
metformin the commonest used antidiabetc agent did not 
have any significant actions on either the liver histology 
but decreased the adiponectin amounts [89,151]. Vitamin E 
has a robust antioxidant action that can confer protection 
to bodies cells against Oxidative stress [152]. It had been 
thought to be an alternate medicine advocated for NAFLD 
as well as NASH. It enhances liver histology as well as 
displays certain adv actions in case of non Diabetes mel-
litus cases with NASH, as well as apparently it enhances 
adiponectin amounts [153]. Nevertheless, it has no efficacy 
in NASH cases with T2DM [153]. In case of mouse models, 
adiponectin represses hepatic lipid collection by lipid me-
tabolism collection by escalated FA oxidation along with 
reduction in DNL [94]. Adiponectin has anti inflammation, 
anti fibrotic as well as anti apoptosis action [154]. Adiponec-
tin delivery escalates hepatic steatosis along with inflam-
mation [154]. Moreover adiponectin expression has an in-
verse association with tumor size as well as recurrence [155].
Leptin
Leptin is a hormone possessing appetite repression 
actions, that gets liberated from fat cells. It controls food 
consumption, body fat in addition to insulin sensitivity 
[156]. In animal models it is believed to escalate lipid me-
tabolism in case of non AT’s [157]. Nevertheless, in liver, it 
accelerates hepatic IR, that results in liver steatosis. Fur-
ther it escalates -liver fibrosis [156]. Leptin delivery might 
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escalate proinflammatory along with fibrogenic reaction 
in the liver through procollagen 1 along with transforming 
growth factor beta (TGF-β1) [158]. Nevertheless, in humans 
its actions are not certain. Escalated circulating amounts 
are present in patients with NASH [159]. Leptin expression 
has a positive association with robustness of steatosis, in-
flammation along with fibrosis [160]. Leptin expression has 
a positive association with cell proliferation in HCC, as 
validated by proliferation marker Ki67 [133].
Resistin
Resistin is a proinflammatory adipocyte obtained mod-
ulator of hepatic IR [161]. Further it gets expressed in liver 
as well. It is correlated with hepatic lipogenesis as well as 
liver fibrosis [162]. Circulating Resistin amounts are escalat-
ed in patients with NAFLD as well as NASH, with circu-
lating Resistin amounts in NAFLD patients are associated 
with the robustness of steatosis, inflammation along with 
fibrosis [162]. Escalated Resistin amounts are believed to be 
correlated with IR. In subjects with NAFLD Pioglitazone 
therapy escalates insulin sensitivity along with reduces 
plasma Resistin amounts [163].
Ghrelin
Ghrelin represents an anti-inflammatory Adipokine. 
It is the endogenous ligand for growth hormone secreta-
gogue receptor possessing a peptide structure having 28 
amino acids [164]. In patients with NAFLD lesser Ghrelin 
are correlated with IR [165]. Plasma Ghrelin amounts possess 
a significant association with liver function. Nevertheless, 
Ghrelin amounts are not influenced by Pioglitazone in 
the form of one of insulin sensitizers [43]. At the time of as 
well as following NAFLD generation, Ghrelin delivery 
escalates lipid metabolism, inflammation, Oxidative stress 
as well as apoptosis [166]. In mouse models Ghrelin result-
ed in reduction in TG amounts as well as the cytokines 
TNF-α, IL-6 as well as ameliorated lipotoxicity via auto-
phagy activation in addition to hampering NFκB [167]. In 
toto Ghrelin might work as a biomarker for both diagnosis 
and management of non alcoholic fatty liver disease.
 
Figure 5. NAFLD robustness anticipation
Legend for Figure 5
Courtesy ref no-30-Adipokines as diagnostic markers and therapeutic targets in NAFLD and NASH. Adipokines that are secreted 
from adipose tissues are classified into anti-inflammatory adipokines and pro-inflammatory adipokines. Anti-inflammatory adipokines 
including adiponectin, irisin, and ghrelin inhibit the development and progression of NAFLD and NASH, whereas pro-inflammatory 
adipokines including leptin, resistin, and visfatin promote the development and progression of NAFLD and NASH.
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Irisin
Irisin is a myokine liberated from skeletal muscles on 
shivering in addition to exercise stmn [168,169]. Fibronectin 
typeIII domain containing 5 precursors (FNDC5) is the 
precursor of Irisin. FNDC5/Irisin facilitate thermogene-
sis in AT via ERK as well as p38pathways [170]. It causes 
enhancement of glucosehomeostasis along with IR, be-
sides resulting in weight [171] reduction. In the recent past 
FNDC5/Irisin induction was obtained at the time of adi-
pocytes differentiation, as well as can get over liberated 
from human visceral (VAT) as well as subcutaneous (SAT) 
adipose tissue [172]. It is believed to be a compensatory 
action. In agreement with this circulating Irisin amounts 
are escalated in NAFLD patients, besides being positively 
associated with portal inflammation [173], that is further 
thought to be a compensatory action.
Visfatin
Visfatin represents an inflammatory adipokine enzyme 
(alias nicotinamide phospho ribosyl transferase as well 
as pre B cell colony enhancing factor). Visfatin amounts 
are escalated in T2DM in addition to insulin resistant 
situations [174]. Circulating Visfatin amounts are further es-
calated in NAFLD patients, besides being correlated with 
hepatic steatosis as well as fibrosis [175]. Nevertheless, they 
don’t get influenced by insulin sensitizers like pioglita-
zone, rosiglitazone as well as metformin [176].
4.4 NAFLD as well as - NASH --Obtained HCC
Pathogenesis of NAFLD as well as - NASH -- 
associated -HCC
HCC being the 3rd commonest etiology of cancer asso-
ciated mortality [177]. NAFLD as well as NASH associated 
HCC represents the most rapidly escalated indication for 
liver transplantation [178]. Cirrhosis exists in about 60% of 
cases of NAFLD as well as NASH associated HCC [178]. 
This points that HCC can get stimulated from NAFLD 
as well as NASH without cirrhosis. Hence belief is that 
inflammatory parameters will also have a key part in 
NAFLD/NASH-obtained HCC.
Gut obtained endotoxin
Already detailed how Gut obtained endotoxins work 
in the form of alternative inflammatory parameters have a 
significant part in the generation of NAFLD/NASH. The 
amounts of LPS, alias endotoxins are further escalated in 
portal as well as peripheral venous veins of patients with 
HCC [179]. They facilitate significantly the invasion poten-
tial besides inducing epithelial –mesenchymal transition 
(EMT), despite them hampering tumor growth as well 
[180]. LPS stimulates JNK in addition to MAPK through 
TLR4 in HCC cells while hampering of JNK in addition 
to MAPK causes a significant reduction in EMT taking 
place [180]. Hence the LPS-TLR4 signaling might be one of 
the lucrative pathways in controlling the propagation from 
NAFLD-NASH to HCC [181].
Adipokines
Adipokines represent inflammatory parameters asso-
ciated with HCC generation. Expression of adiponectin 
in human HCC has an inverse association with the tumor 
size [182]. It escalates phosphorylation of c-jun N terminal 
kinase (JNK) as well as activation of caspase 3 resulting 
in apoptosis in HCC [182]. Hampering of JNK phospho-
rylation avoids anti apoptotic actions of adiponectin [182]. 
Adiponectin has a chemoshielding, besides hepatoshield-
ing actions through sulfatase2 (SULF2) in HCC [183]. 
Adiponectin deletion facilitates fibrosis as well as HCC 
propagation in a choline deficient NASH mouse model 
[184]. Conversely high amounts of circulating adiponectin 
makes it feasible to anticipate the subsequent generation 
of HCC along with poor HCC survival [185]. Moreover ad-
iponectin hampers the oncogenic action of leptin on cell 
proliferation, migration as well as invasion of HCC [155].
Leptin expression is escalated in hepatoma tissues as 
well as cell lines [186]. Regulatory T Cells(TRegs), effector 
CD 4+T cells, as well as CD 8+T cells result in stimula-
tion of the expression of the Leptin receptor (LEPR) in 
the liver following generation of HCC [186]. Macrophages 
as well as, dendritic cells, upregulate LEPR expression on 
the T Cells. Leptin hampers activation of TRegs as well as 
function [186]. Escalated Leptin expression in HCC is cor-
related with the expression of human telomerase reverse 
transcriptase (hTERT) [187]. Leptin might possess a key 
part in obesity associated tumorigenesis. Adipokines that 
include adiponectin along with Leptin are critical actors 
in obesity associated conditions as well as might be impli-
cated in the etiopathogenesis of NAFLD as well as HCC.
Diagnostic as well as - -Therapeutic target in NAFLD 
as well as - NASH --Obtained HCC-Hepatokines
The liver is an organ which liberates cytokines, known 
as hepatokines. Adipose tissue (AT) in NAFLD, having 
the properties of hepatic TG collection, has a key part 
in facilitation of FFA uptake into the liver via lipolysis 
[45]. Hence the part of adipokines from AT, that yields 
energy source for the generation of NAFLD, would be 
very significant in the liver. Conversely, lipid droplets 
collection by itself does not influence inflammation as 
well as is believed to be simple steatosis. The propaga-
tion from NAFLD to NASH to HCC needs extra factors 
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like oxidative stress, mitochondrial impairment as well as 
endoplasmic reticulum (ER) Stress [63,188]. Another signif-
icant factors facilitating NASH in simple steatosis is free 
nonesterified cholesterol as well as its oxidized products 
[189]. They are cytotoxic, influencing synergistic actions 
with TNF, that is markedly escalated in NASH patients 
[189]. Hence hepatokines liberated from liver might have an 
impact of potency in the propagation of NAFLD to NASH 
to HCC (Figure 6) greater propagation.
α2-HS- glycoprotein (Fetuin A as well as - Fetuin B)
Fetuin A, that is one of the liberated glycoproteins is 
believed to be the 1st hepatokine demonstrated to be corre-
lated with metabolic diseases [190]. Fetuin A gets positively 
correlated with hepatic steatosis as well as IR1 [191]. Its 
amounts are escalated in patients with NAFLD, NASH in 
addition to T2DM [192]. In the form of a significant source 
of NAFLD generation, FFA escalates proinflammatory 
Fetuin A expression [24]. FFA stimulated Fetuin A works 
as an endogenous ligand of TLR4, as well as accelerates 
lipid modulated insulin resistance [193]. FFA can further 
escalate the recruiting of NFκB to the Fetuin A promoter 
as well as escalate the generation as well as liberation of 
Fetuin Ain primary hepatocytes [194]. Pioglitazone signifi-
cantly represses serum Fetuin A amounts in patients with 
T2DM [195]. Pioglitazone hampers mRNA as well as pro-
tein amounts of hepatic Fetuin A along with oral delivery 
of pioglitazone in mice partly mitigated IR with reduction 
in hepatic Fetuin A expression [196]. These data point that 
Fetuin A might serve as a therapeutic target of NAFLD/
NASH as well as IR. Moreover circulating Fetuin A 
amounts are escalated in patients with HCC [197]. Fetuin 
B -might also work out to be an independent pointer of 
NAFLD generation [198]. It also stimulates hepatic steato-
sis, IR, glucose intolerance [166,199]. It results in phospho-
rylation amounts as well as exacerbates LXR/SREBP1c 
modulated hepatic lipogenesis [200]. Conversely, circulat-
ing Fetuin A as well as circulating Fetuin B amounts in 
NAFLD patients have a negative correlation with liver 
fibrosis [201].
 
Figure 6. the propagation of NAFLD to NASH to HCC
Legend for Figure 6
Courtesy ref no-30-Hepatokines that are secreted from the liver are closely associated with the progression from NAFLD to NASH 
to HCC. Hepatokines including Fetuin-A, Fetuin-B, RBP4, and FGF19 play an important role in NAFLD and NASH. They are 
associated with hepatic lipid accumulation, insulin resistance, and inflammatory signaling pathways. Additionally, ANGPTL4 and 8 
tend to function in opposite ways in HCC tumorigenesis.
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Retinol Binding protein-4 (RBP4)
The liver has a central part in Vitamin A metabolism. 
In NAFLD hepatic Vitamin A homeostasis gets disturbed 
[202]. RBP4 is a particular Retinol/Vitamin A carrier protein 
liberated from the liver. Further it also gets liberated from 
adipocytes along with macrophages [203]. Serum RBP4 
amounts are correlated with NAFLD generation [204]. 
Circulating RBP4 amounts have a positive association 
with body mass index (BMI) as well as IR [205]. In case of 
moderate to severe NASH, escalated amounts of RBP4 
was association with lobular inflammation in addition 
to fibrosis scores [206]. In case of cirrhosis, expression of 
RBP4 escalated hepatic glucose generation, but not insu-
lin sensitivity [207]. One knows that Vitamin A homeostasis 
is impaired in addition to decreased secondary to liver fi-
brosis as well as cirrhosis. Significantly escalated amounts 
of RBP4 might become a marker for NAFLD generation, 
along with the lower amounts of RBP4 might further be a 
marker for propagation of NASH with fibrosis in NAFLD 
stages [204].
Hepassocin (HPS)
Hepassocin is a hepatocyte obtained fibrinogen corre-
lated peptide (HFREP-1), a hepatokine which is implicat-
ed in during liver regeneration [208]. In case of mice along 
with human patients with NAFLD, plasma HPS amounts 
are escalated [209]. Overexpression of hepassocin escalated 
hepatic lipid collection, besides NAFLD activity scores 
(NAS), while its removal enhances them [209,210]. Serum 
HPS amounts are escalated with the amounts of inflam-
matory cytokines in addition to lipogenic gene expres-
sion [210]. HPS stimulated hepatic steatosis gets triggered 
via the extracellular signal regulated kinase (ERK1/2)-
based pathway [210]. FFA stimulates expression of HPS 
[211,212]. Oleic acid the maximum distributed unsaturated 
fatty acids, stimulates expression of HPS vis the Signal 
Transducers and Activators of Transcription3 (STAT3) 
signaling [211]. Palmitate, that has the maximum content 
of saturated fatty acids, stimulates expression of HPS via 
endoplasmic reticulum (ER) stress – modulated p38 acti-
vation by C/EBPβ in primary hepatocytes [212]. In addition 
to that hepatic expression of HPS gets escalated by partial 
hepatectomy in mice, as well as gets stimulated by hepatic 
nuclear factor 1(HNF-1α) via the IL-6/STAT3 pathway 
[213]. Delivery of HPS confers protection against liver dam-
age as well as escalates survival in rats with hepatitis [214]. 
Liver particular expression of HPS gets suppressed with 
the downregulation of the correlation of HNF1 alpha with 
reduced amounts of hepassocin in human Hepatocellular 
carcinoma [213,215].
Fibroblast -growth -factor 19 and -21 (FGF19 as 
well as - - FGF21)
FGF19 as well as FGF21 belong to the FGF19 family, 
which needs the Klotho proteins as cofactors. They stim-
ulate FGFR4 along with Klotho, that has an abundance of 
expression in hepatocytes [216]. FGF19 as well as FGF21 
have the role of controlling glucose, lipid as well as bile 
acid metabolism [217].
Fibroblast -growth -factor 19 (FGF19)
In case of NASH, the amounts of serum FGF19, Fibro-
blast growth factor receptor 4(FGF R4), along with bile 
acids are significantly escalated, that causes dysfunction 
of FXR as well as FGFR4 modulated signaling [218]. In cas-
es of NASH, FAF analogue significantly causes reduction 
in hepatic lipid accumulation. Conversely up regulation 
of FGF19 is correlated with the propagation, recurrence, 
in addition to worst prognosis of HCC [219]. The β- Klotho 
proteins are further escalated in liver as well as serum of 
subjects with HCC [220].
Fibroblast -growth -factor 21 (FGF21)
The hepatokine FGF21 possess advantageous actions 
on hepatic lipid metabolism. It escalates lipid oxidation, 
represses DNL, in addition to escalate insulin resistance 
by inhibiting mammalian target of rapamycin complex1 
(mTOR) [221]. Hepatic FGF21 expression possesses a 
positive association with adipocyte in addition to intra 
hepatic TG, with its serum amounts being escalated by 
significant amounts in subjects with obesity, NAFLD 
as well as T2DM [222]. Serum amounts of FGF21 are es-
calated in obese children with or without NAFLD [223]. 
Escalated amounts of FGF21 are believed to be based on 
the robustness of steatosis, along with positive association 
with NAS [224]. Cases of advanced NASH can be labelled 
on the basis of properties of circulating FGF21 amounts 
in combination with inflammatory factors (cytokeratin 18, 
M30antigen, IL-1Ra, pigment epithelium-based factor, as 
well as osteoprotegrin) [225]. Enhancement of serum as well 
as hepatic FGF21 amounts are seen in cirrhosis as well as 
HCC [226].
Angiopoietin –Like Protein- 8 (betatrophin/
ANGPTL8)
ANGPTL8/betatrophin represent a circulating hepa-
tokine also called TD26 as well as lipasin [227]. It is sig-
nificantly expressed in liver as well as visceral adipose 
tissue (VAT) [228]. Over expression of ANGPTL8 in brown 
adipose tissue (BAT) escalates lipoprotein lipase (LPL) 
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action along with TG uptake [168,229] [reviewed by us in 
169]. Serum ANGPTL8 are significantly escalated in pa-
tients with pre Diabetes as well as type2 Diabetes [230]. It 
has been documented that ANGPTL8 is not implicated in 
Pancreatic βcells expansion, although it has a part in con-
trolling glucose along with lipid metabolism in mice [231,232]. 
In addition ANGPTL8 expansion is significantly esca-
lated in HCC [228]. It crosstalks with SREBP1, secondary 
to which it facilitates lipogenesis along with tumor cell 
proliferation in HCC [228]. Hence it is believed that it has a 
positive association with the tumor size. ANGPTL8 needs 
ANGPTL 3 instead of controlling LPL by itself [229,233]. 
ANGPTL 3 controls TG metabolism by directly hamper-
ing LPL [229,233]. ANGPTL 4 gets markedly expressed in 
liver as well as adipose tissue, in addition to can controls 
TG metabolism by hampering LPL action [229,235]. Never-
theless, ANGPTL 4 expression reduction exists in HCC, 
besides Over expression of ANGPTL4 hamper hepatocar-
cinogenesis along with metastasis of HCC [236].
5. Conclusions
Over the past 2 decades the percentage of HCC cases 
possessing non viral etiology has been escalating at a fast 
pace. Secondary to this the significance of NAFLD/NASH 
obtained HCC has been showing up. At present what holds 
the truth is that management of subjects with NAFLD/
NASH is usually carried out with the utilization of medi-
cines for the treatment of type2 Diabetes mellitus as well 
as hyperlipidemia. The adverse actions which show up 
following the long term utilization have to be taken into 
account. Hence proper therapeutic targets along with FDA 
approved treatments are required at war footing. It is be-
lieved that the causation of failure of generation of a ther-
apy for subjects with NAFLD/NASH in spite of contin-
uous attempts are i) pathogenesis is still not totally clear; 
ii) absence of actions; iii) safety issues. Adipose tissue as 
well as the liver constitute the most significant organs that 
are correlated with lipid metabolism. Hence it is essential 
to watch adipokines as well as hepatokines that can work 
as diagnostic in addition to therapeutic targets as well as 
signaling pathways that get targeted by the present ther-
apies. In addition, to that it needs to get deep insight via 
the classification as per the etiology of NAFLD. It would 
yield a significant point of view for the regulation of the 
metabolic phenotype from NAFLD to NASH to HCC. At 
present it has been accepted that think of NAFLD as being 
occurring secondary to a concert of different parameters 
that include nutritional factors, Gut Microbiota, genetic 
in addition to epigenetic factors as well as adipokines in 
addition to hepatokines. To be able to achieve a successful 
therapy, it is essential to watch different factors in a wider 
perspective.
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